Atlas Trials

Efficacy and Safety of Therapy With IgM-enriched Immunoglobulin With a Personalized Dose vs Standard Dose in Patients With Septic Shock.

Clinical trial NCT04182737 · UNKNOWN

Trial details

NCT number
NCT04182737
Sponsor
Massimo Girardis
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Shock, SepticSepsisHypoglobulinemia
Start date
2020-05-01
Primary completion
2022-02-28
Enrollment
356

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.